Basic and clinical studies on cefetamet pivoxil

Yoshiro Sawae, Kaoru Okada, Yukio Kumagai, Toshiyuki Ishimaru, Koji Takaki, Nobuyuki Shimono, Hiroyasu Misumi, Yoshiyuki Niho

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

We performed basic and clinical studies on cefetamet pivoxil (CEMT-PI), a new oral cephalosporin antibiotic, with the following results. 1) Antimicrobial activity The MICs of cefetamet (CEMT), the active substance of CEMT-PI, against various clinical isolates were determined with an inoculum size of 106cells/ml. The MIC50 was 50 μg/ml for Staphylococcus aureus, >100 for Enterococcus faecalis, 0.78 for Escherichia coli, 0.39 for Klebsiella pneumoniae, 6.25 for Enterobacter cloacae, 0.78 for Enterobacter aerogenes, 1.56 for Serratia marcescens, 0.20 for Proteus mirabilis, 1.56 for Proteus vulgaris, 3.13 for Citrobacter spp. and >100 for Pseudomonas aeruginosa. Its activity against Gram-negative rods except P. aeruginosa was much more potent than those of cephalexin and cefaclor, but a little less so than those of cefixime and cefteram. 2) Clinical efficacy Four patients with pneumonia, 3 with bronchitis, 3 with tonsillitis, 3 with pharyngitis, 1 with gingival abscess, and 1 with cystitis were treated with CEMT-PI at a daily dose of 0.5∼1.0g for 3∼26 days. Clinical response was excellent in 4, good in 6, fair in 1, poor in 2 and unknown in 2 patients. The clinical efficacy rate was 76.9%. Five out of 9 cases which causative strains were isolated were eradicated by CEMT-PI. Heartburn, epigastralgia and abdominal fullness were observed in 3 patients. Eosinophilia was observed in 2 patients and elevated GOT, GPT, AL-P and γ-GTP in one patient.

Original languageEnglish
Pages (from-to)163-169
Number of pages7
JournalCHEMOTHERAPY
Volume38
DOIs
Publication statusPublished - Jan 1 1990

Fingerprint

Pseudomonas aeruginosa
Cefixime
Citrobacter
Cefaclor
Proteus vulgaris
Enterobacter aerogenes
Cephalexin
Enterobacter cloacae
Proteus mirabilis
Heartburn
Tonsillitis
Serratia marcescens
Cystitis
Pharyngitis
Bronchitis
Enterococcus faecalis
Klebsiella pneumoniae
Eosinophilia
Cephalosporins
Guanosine Triphosphate

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)
  • Infectious Diseases
  • Pharmacology
  • Drug Discovery
  • Oncology

Cite this

Sawae, Y., Okada, K., Kumagai, Y., Ishimaru, T., Takaki, K., Shimono, N., ... Niho, Y. (1990). Basic and clinical studies on cefetamet pivoxil. CHEMOTHERAPY, 38, 163-169. https://doi.org/10.11250/chemotherapy1953.38.Supplement1_163

Basic and clinical studies on cefetamet pivoxil. / Sawae, Yoshiro; Okada, Kaoru; Kumagai, Yukio; Ishimaru, Toshiyuki; Takaki, Koji; Shimono, Nobuyuki; Misumi, Hiroyasu; Niho, Yoshiyuki.

In: CHEMOTHERAPY, Vol. 38, 01.01.1990, p. 163-169.

Research output: Contribution to journalArticle

Sawae, Y, Okada, K, Kumagai, Y, Ishimaru, T, Takaki, K, Shimono, N, Misumi, H & Niho, Y 1990, 'Basic and clinical studies on cefetamet pivoxil', CHEMOTHERAPY, vol. 38, pp. 163-169. https://doi.org/10.11250/chemotherapy1953.38.Supplement1_163
Sawae, Yoshiro ; Okada, Kaoru ; Kumagai, Yukio ; Ishimaru, Toshiyuki ; Takaki, Koji ; Shimono, Nobuyuki ; Misumi, Hiroyasu ; Niho, Yoshiyuki. / Basic and clinical studies on cefetamet pivoxil. In: CHEMOTHERAPY. 1990 ; Vol. 38. pp. 163-169.
@article{da675c92408d476eb4e15496d6e6cdc2,
title = "Basic and clinical studies on cefetamet pivoxil",
abstract = "We performed basic and clinical studies on cefetamet pivoxil (CEMT-PI), a new oral cephalosporin antibiotic, with the following results. 1) Antimicrobial activity The MICs of cefetamet (CEMT), the active substance of CEMT-PI, against various clinical isolates were determined with an inoculum size of 106cells/ml. The MIC50 was 50 μg/ml for Staphylococcus aureus, >100 for Enterococcus faecalis, 0.78 for Escherichia coli, 0.39 for Klebsiella pneumoniae, 6.25 for Enterobacter cloacae, 0.78 for Enterobacter aerogenes, 1.56 for Serratia marcescens, 0.20 for Proteus mirabilis, 1.56 for Proteus vulgaris, 3.13 for Citrobacter spp. and >100 for Pseudomonas aeruginosa. Its activity against Gram-negative rods except P. aeruginosa was much more potent than those of cephalexin and cefaclor, but a little less so than those of cefixime and cefteram. 2) Clinical efficacy Four patients with pneumonia, 3 with bronchitis, 3 with tonsillitis, 3 with pharyngitis, 1 with gingival abscess, and 1 with cystitis were treated with CEMT-PI at a daily dose of 0.5∼1.0g for 3∼26 days. Clinical response was excellent in 4, good in 6, fair in 1, poor in 2 and unknown in 2 patients. The clinical efficacy rate was 76.9{\%}. Five out of 9 cases which causative strains were isolated were eradicated by CEMT-PI. Heartburn, epigastralgia and abdominal fullness were observed in 3 patients. Eosinophilia was observed in 2 patients and elevated GOT, GPT, AL-P and γ-GTP in one patient.",
author = "Yoshiro Sawae and Kaoru Okada and Yukio Kumagai and Toshiyuki Ishimaru and Koji Takaki and Nobuyuki Shimono and Hiroyasu Misumi and Yoshiyuki Niho",
year = "1990",
month = "1",
day = "1",
doi = "10.11250/chemotherapy1953.38.Supplement1_163",
language = "English",
volume = "38",
pages = "163--169",
journal = "CHEMOTHERAPY",
issn = "0009-3165",

}

TY - JOUR

T1 - Basic and clinical studies on cefetamet pivoxil

AU - Sawae, Yoshiro

AU - Okada, Kaoru

AU - Kumagai, Yukio

AU - Ishimaru, Toshiyuki

AU - Takaki, Koji

AU - Shimono, Nobuyuki

AU - Misumi, Hiroyasu

AU - Niho, Yoshiyuki

PY - 1990/1/1

Y1 - 1990/1/1

N2 - We performed basic and clinical studies on cefetamet pivoxil (CEMT-PI), a new oral cephalosporin antibiotic, with the following results. 1) Antimicrobial activity The MICs of cefetamet (CEMT), the active substance of CEMT-PI, against various clinical isolates were determined with an inoculum size of 106cells/ml. The MIC50 was 50 μg/ml for Staphylococcus aureus, >100 for Enterococcus faecalis, 0.78 for Escherichia coli, 0.39 for Klebsiella pneumoniae, 6.25 for Enterobacter cloacae, 0.78 for Enterobacter aerogenes, 1.56 for Serratia marcescens, 0.20 for Proteus mirabilis, 1.56 for Proteus vulgaris, 3.13 for Citrobacter spp. and >100 for Pseudomonas aeruginosa. Its activity against Gram-negative rods except P. aeruginosa was much more potent than those of cephalexin and cefaclor, but a little less so than those of cefixime and cefteram. 2) Clinical efficacy Four patients with pneumonia, 3 with bronchitis, 3 with tonsillitis, 3 with pharyngitis, 1 with gingival abscess, and 1 with cystitis were treated with CEMT-PI at a daily dose of 0.5∼1.0g for 3∼26 days. Clinical response was excellent in 4, good in 6, fair in 1, poor in 2 and unknown in 2 patients. The clinical efficacy rate was 76.9%. Five out of 9 cases which causative strains were isolated were eradicated by CEMT-PI. Heartburn, epigastralgia and abdominal fullness were observed in 3 patients. Eosinophilia was observed in 2 patients and elevated GOT, GPT, AL-P and γ-GTP in one patient.

AB - We performed basic and clinical studies on cefetamet pivoxil (CEMT-PI), a new oral cephalosporin antibiotic, with the following results. 1) Antimicrobial activity The MICs of cefetamet (CEMT), the active substance of CEMT-PI, against various clinical isolates were determined with an inoculum size of 106cells/ml. The MIC50 was 50 μg/ml for Staphylococcus aureus, >100 for Enterococcus faecalis, 0.78 for Escherichia coli, 0.39 for Klebsiella pneumoniae, 6.25 for Enterobacter cloacae, 0.78 for Enterobacter aerogenes, 1.56 for Serratia marcescens, 0.20 for Proteus mirabilis, 1.56 for Proteus vulgaris, 3.13 for Citrobacter spp. and >100 for Pseudomonas aeruginosa. Its activity against Gram-negative rods except P. aeruginosa was much more potent than those of cephalexin and cefaclor, but a little less so than those of cefixime and cefteram. 2) Clinical efficacy Four patients with pneumonia, 3 with bronchitis, 3 with tonsillitis, 3 with pharyngitis, 1 with gingival abscess, and 1 with cystitis were treated with CEMT-PI at a daily dose of 0.5∼1.0g for 3∼26 days. Clinical response was excellent in 4, good in 6, fair in 1, poor in 2 and unknown in 2 patients. The clinical efficacy rate was 76.9%. Five out of 9 cases which causative strains were isolated were eradicated by CEMT-PI. Heartburn, epigastralgia and abdominal fullness were observed in 3 patients. Eosinophilia was observed in 2 patients and elevated GOT, GPT, AL-P and γ-GTP in one patient.

UR - http://www.scopus.com/inward/record.url?scp=0025605361&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025605361&partnerID=8YFLogxK

U2 - 10.11250/chemotherapy1953.38.Supplement1_163

DO - 10.11250/chemotherapy1953.38.Supplement1_163

M3 - Article

AN - SCOPUS:0025605361

VL - 38

SP - 163

EP - 169

JO - CHEMOTHERAPY

JF - CHEMOTHERAPY

SN - 0009-3165

ER -